Free Trial

ARAVIVE (ARAV) Competitors

ARAVIVE logo
$0.04 0.00 (0.00%)
As of 07/9/2025

ARAV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALA

Should you be buying ARAVIVE stock or one of its competitors? The main competitors of ARAVIVE include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

ARAVIVE vs. Its Competitors

ARAVIVE (NASDAQ:ARAV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, 180 Life Sciences had 1 more articles in the media than ARAVIVE. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for ARAVIVE. 180 Life Sciences' average media sentiment score of 1.87 beat ARAVIVE's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
ARAVIVE Neutral
180 Life Sciences Very Positive

180 Life Sciences has lower revenue, but higher earnings than ARAVIVE.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARAVIVE$9.14M0.32-$76.32MN/AN/A
180 Life SciencesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
ARAVIVEN/A N/A N/A
180 Life Sciences N/A N/A N/A

35.8% of ARAVIVE shares are held by institutional investors. 60.4% of ARAVIVE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ARAVIVE beats 180 Life Sciences on 3 of the 5 factors compared between the two stocks.

Get ARAVIVE News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARAV vs. The Competition

MetricARAVIVEMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.99B$5.61B$9.11B
Dividend YieldN/A2.39%5.24%4.01%
P/E RatioN/A20.5827.9620.25
Price / Sales0.32292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / BookN/A7.638.045.49
Net Income-$76.32M-$55.05M$3.18B$250.27M
7 Day PerformanceN/A8.54%3.67%4.80%
1 Month PerformanceN/A5.51%4.09%7.68%
1 Year PerformanceN/A2.03%29.58%16.36%

ARAVIVE Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ATNFW
180 Life Sciences
N/A$0.01
+2.5%
N/A-2.4%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
flat
N/A-83.4%$0.00N/A0.002Gap Down
AIMDW
Ainos
N/A$0.12
-0.2%
N/A+70.4%$0.00$106.21K0.0040Gap Down
ALVOW
Alvotech
N/A$1.90
+9.8%
N/A-42.1%$0.00$585.60M0.004Gap Down
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.02
flat
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.09
-14.2%
N/A+213.1%$0.00$38.00M0.0070Gap Up
BTMDW
biote
N/A$0.01
+20.1%
N/A-97.5%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.06
-14.8%
N/A-62.1%$0.00N/A0.008Gap Down
CALA
Calithera Biosciences
N/A$0.00
flat
N/A-99.0%$0.00N/A0.0060Gap Down

Related Companies and Tools


This page (NASDAQ:ARAV) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners